Why the study?
Does a fixed-dose combination of valsartan and rosuvastatin improve the achievement of BP and LDL-C targets in Korean patients with concomitant hypertension and hyperlipidemia?
Does a fixed-dose combination of valsartan and rosuvastatin improve the achievement of BP and LDL-C targets in Korean patients with concomitant hypertension and hyperlipidemia?
A fixed-dose combination of valsartan and rosuvastatin is effective and well-tolerated for achieving BP and LDL-C targets in patients with concomitant hypertension and hyperlipidemia in a real-world setting.
Answers are grounded in this paper and cite their sources.
Supports effectiveness of the study drug for BP and LDL-C goals in Korean patients; leaves open confirmation in randomized trials.
Purpose: ) in Korean patients with concomitant hypertension and hyperlipidemia. Patients and Methods: A total of 1008 eligible patients with concomitant hypertension and hyperlipidemia were enrolled and treated for 12 weeks. Both upward and downward drug dose titrations were allowed based on the investigator's discretion. This study evaluated the effectiveness of the study drug, defined by the percentage of patients achieving the blood pressure (BP) and low-density lipoprotein cholesterol (LDL-C) treatment targets. Additionally, regression analyses were conducted to evaluate the factors associated with the effectiveness and safety of the study drug. Of the 1008 patients enrolled in the study, 911 were analyzed for clinical effectiveness. Results: At 12 weeks, 84.6% and 75.9% of patients treated with the study drug achieved their BP and LDL-C targets, respectively, and 64.8% of patients achieved both targets simultaneously. Furthermore, the percentage of patients who achieved their BP and LDL-C treatment targets demonstrated a trend across the respective risk groups; the higher the risk group, the lower the success of attaining the respective target. This trend was also observed regardless of the prior antihypertensive and/or lipid-lowering treatments. According to regression analysis, poor metabolic profiles, including a higher body mass index (BMI) and higher BP and LDL-C levels at baseline, were significantly associated with treatment failure for BP. Among the 1005 patients included in the safety analysis, 17 patients (1.7%) experienced serious adverse events; however, none were considered related to the study drug. Conclusion: The study drug used for the treatment of concomitant hypertension and hyperlipidemia in a real-world setting was effective and was well tolerated. Therefore, the study drug is suggested as a good alternative to increase patient convenience and compliance, particularly in those taking multiple medications.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: